Status:
COMPLETED
Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors
Lead Sponsor:
Eli Lilly and Company
Conditions:
Cancer
Refractory Solid Tumor
Eligibility:
All Genders
1-18 years
Phase:
PHASE1
Brief Summary
The purpose of this clinical research study is to establish the maximum tolerated dose and recommended Phase II dose of Erbitux™ in combination with Irinotecan in pediatric and adolescent patients wit...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed diagnosis of a solid tumor which has progressed on, or following standard therapy, or for which no standard effective therapy is known.
- Children age 1-18 years.
Exclusion
- Presence of active infection.
- Requirement to receive concurrent chemotherapy immunotherapy, radiotherapy, or any other investigational drug while on study.
- Inadequate bone marrow, hepatic, or renal function.
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2008
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00110357
Start Date
August 1 2005
End Date
March 1 2008
Last Update
December 24 2015
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Phoenix Children'S Hospital
Phoenix, Arizona, United States, 85016
2
University Of Arizona Health Sciences Center
Tucson, Arizona, United States, 85724
3
The Children'S Hospital
Denver, Colorado, United States, 80218
4
University Of Florida
Gainesville, Florida, United States, 32610